肥胖症与GLP-1药物_一项基于理赔数据的分析（英）_26页_908kb

Summary of Obesity and GLP-1 Drugs Report

Overview

This white paper analyzes trends in obesity and GLP-1 (glucagon-like peptide-1) drug prescriptions among adults from 2019 to 2024 using a database of over 51 billion commercial healthcare claims. It examines diagnoses, prescription rates, side effects, and associated treatments.

Key Findings

• Obesity Diagnosis: The percentage of adults diagnosed with overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024, representing a 50.7% relative increase. Morbid obesity climbed from 3.1% to 5.2%.
• GLP-1 Drug Prescriptions: GLP-1 prescription rates rose sharply from 0.9% to 4.0% among adults, a 363.7% increase. Usage for obesity purposes increased to 2.05%, showing a 586.7% rise.
• Demographic Trends: Younger adults (aged 18-39) saw a 587.8% increase in GLP-1 prescriptions, while bariatric surgery rates declined by 41.8% overall.
• Co-occurring Conditions: After first GLP-1 prescription, conditions like pancreatitis increased by 80.1% in non-diabetic patients, alongside other side effects.
• Other Treatments: Bariatric surgery rates dropped, and behavioral health services decreased, particularly among GLP-1 users.
• Overall Trends: Fewer than 20% of adults with obesity received GLP-1 drugs, bariatric surgery, or behavioral health services in 2024, indicating low utilization of available treatments.

Conclusion

The study highlights rapid adoption of GLP-1 drugs with potential side effects, while obesity diagnosis rates surged. Implications include the need for better integration of treatments and monitoring for adverse effects, informing patients, providers, payors, and policymakers.